NCT02937584View on ClinicalTrials.gov

A Study to Assess the Effects of PT001 and PT005 MDI on Specific Image Based Parameters in Subjects With Moderate to Severe COPD

PHASE3CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

December 29, 2016

Primary Completion Date

May 28, 2018

Study Completion Date

May 28, 2018

Conditions
COPD, Chronic Obstructive Pulmonary Disease
Interventions
DRUG

GP MDI (PT001) 14.4 μg

Glycopyrronium

DRUG

FF MDI (PT005) 9.6 μg

Formoterol Fumarate

Trial Locations (2)

2650

Research Site, Edegem

5101

Research Site, Erpent

Sponsors
All Listed Sponsors
lead

Pearl Therapeutics, Inc.

INDUSTRY